Participated · Equity · Sep 2022

Wizaly is a SaaS platform that provides multichannel marketing attribution, decision support, and customer-insight generation using artificial intelligence. Its proprietary hybrid consent/non-consent tracking has been referenced by the CNIL as a GDPR-compliant technical solution. The platform processes more than 200 million brand–customer interactions daily and represents over 5,000 person-days of development. Wizaly serves large accounts (Air France, Engie), as well as SMEs and startups, and reports triple-digit annual growth. Founded in 2017 by engineers and digital entrepreneurs, the company is present in France and the U.S. (Chicago), where it already generates 20% of its revenue. The company plans to use recent funding to accelerate technical development and international expansion, aiming to make the U.S. its primary market by 2026 and to open offices in the U.K. and Germany.

Participated · Equity · May 2022

Germitec develops and manufactures UV-C high-level disinfection systems aimed primarily at disinfecting ultrasound probes used in fertility (IVF), gynecology, cardiology and ENT. Its products are available in 40 countries and protect approximately 2.2 million patients worldwide each year. The company received an FDA De Novo granted in August 2024 and cites a U.S. market opportunity of 60,000 units. Germitec says it is positioned to double its revenue every year with profitability on the horizon. Proceeds from the recent financing will be used to scale U.S. operations, accelerate commercial adoption and invest in R&D to expand its product portfolio. Combined with prior financing from the European Investment Bank in 2023, the company expects sustained growth over the next two years. GERMITEC designs and commercializes automated UV‑C high‑level disinfection (HLD) systems for external, vaginal, rectal and transesophageal ultrasound probes, including products Hypernova Chronos, Antigermix AE1 and the PROUV traceability system. The company positions its chemical‑free devices as faster, simpler and cleaner replacements for wipes, soaking and hydrogen peroxide workflows and notes approvals in over 35 countries. GERMITEC says its UV‑C HLD address Healthcare‑Acquired Infections and aims to make UV‑C HLD a standard of care; its market opportunity is cited at about €245M. The company has 15 years of product development experience and won the 2020 Prix Galien for Best Medical Device. With the new capital and management team, GERMITEC plans European and international commercial expansion and is preparing a U.S. go‑to‑market strategy following planned FDA clearance. The financing and leadership changes are framed as steps to transform GERMITEC into a high‑growth commercial company and to continue product innovation and operational structuring.

Participated · Equity · Jun 2021

FineHeart is a clinical-stage medical device company headquartered in Bordeaux and Tours that is building FlowMaker®, the first fully implantable cardiac output accelerator designed for advanced heart failure. The intraventricular pump synchronizes with native heart contractions, preserves physiological blood flow, and is wirelessly recharged via transcutaneous energy transfer, sharply lowering infection risk. Implantation is performed on a beating heart through a minimally invasive 90-minute procedure, giving surgeons a familiar workflow. The technology addresses a market of about 200,000 patients a year and initially targets the 50,000 most severe cases not served by current LVADs, an opportunity valued at more than €5 billion. FineHeart protects its platform with 160 patents across 27 families. With the latest funding, the company plans to industrialize FlowMaker® hardware, run clinical trials, and solidify its leadership in active implantable medical devices (AIMDs).

Participated · Series A · May 2019

TreeFrog Therapeutics develops stem cell–derived cell therapies and a proprietary C‑Stem™ high‑throughput cell encapsulation platform to mass‑produce and differentiate stem cells in industrial bioreactors. The company intends to deploy C‑Stem for clinical‑grade manufacturing and advance a pipeline of cell therapies toward the clinic, and to open technology hubs in Boston and Kobe. TreeFrog plans to use the new funds to scale manufacturing and support clinical development. Since incorporation in November 2018 in Bordeaux, France, the team has grown to more than 50 employees and moved into a 13,000 sq. ft. production facility in June 2020. The company previously raised over €10M ($11.7M) in 2019 and joined the FrenchTech120 in January 2020. Current leadership changes tied to the round include the appointment of Frederic Desdouits as CEO and the creation of a U.S. subsidiary to be led by co‑founder Kevin Alessandri. TreeFrog Therapeutics develops C‑Stem, a proprietary 3D cell culture system designed to enable mass production of pluripotent stem cells while preserving genomic integrity. C‑Stem is compatible with conventional bioreactors and aims to lower cell‑therapy production costs and accelerate bioproduction for diseases such as Parkinson’s, type 1 diabetes, and heart failure. The company says C‑Stem will turn into a bioproduction platform to supply stem cells and differentiated therapeutic cells and targets first clinical‑grade batches by 2021. TreeFrog has secured intellectual property, closed a Series A round, and established operations and governance. The recent funding will be used to attain cGMP certification (a prerequisite for FDA approval), extend production capacity, and further develop the C‑Stem platform. Management is recruiting executives to lead cGMP efforts and scale manufacturing. TreeFrog Therapeutics, incorporated in November 2018 and based in Bordeaux, France, has developed C-Stem™, a proprietary 3D stem cell culture platform intended to provide scalable, higher-quality therapeutic cells while reducing treatment costs. The company aims to apply the technology across multiple indications including Huntington’s disease, Parkinson’s disease, heart failure, diabetes and NASH through proprietary and collaborative research programs. TreeFrog plans to transition C-Stem™ to cGMP standards by 2021 and targets a first-in-man clinical trial in 2024. Management is led by Kevin Alessandri (CEO & CTO) and Maxime Feyeux (President, CSO). The company pursues strategic partnerships and co-developments with pharma and cell therapy initiatives to accelerate clinical development and facilitate market access. Financially, TreeFrog completed a Series A financing and obtained non-dilutive public support to advance its development and manufacturing plans.

Participated · Series A · Jul 2018

Antabio is a clinical-stage biopharmaceutical company based in Labège, France, led by CEO and founder Marc Lemonnier. It develops novel and highly differentiated antibacterial treatments addressing CDC/WHO critical priority drug-resistant pathogens, with particular emphasis on life‑threatening respiratory infections and hospital-acquired infections. Its lead program, MEM-ANT3310, is a next‑generation antibacterial combination currently in Phase 1 trials being developed for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE). The company’s pipeline also includes ANT3273, an inhalation treatment targeting Pseudomonas aeruginosa infections in chronic pulmonary disease patients, and ANT2681, a metallo beta‑lactamase (MBL) inhibitor intended to be combined with meropenem for MBL-producing CRE, including NDM strains. Antabio plans to use the recent financing to support the clinical development of MEM-ANT3310. Antabio is a private biopharmaceutical company founded in 2009 in Labège, France, focused on developing novel antibacterial resistance-breakers for high unmet medical needs. Its core programs include a metallo ß-lactamase inhibitor to be combined with a carbapenem for nosocomial infections and a first-in-class inhibitor of Pseudomonas virulence (PEi) for chronic respiratory infections. The PEi program is being developed as an inhaled adjunct to standard-of-care antibiotics targeting the LasB elastase to reduce tissue damage, inflammation, and pathogen persistence in cystic fibrosis lungs. The company has received Wellcome Trust Seeding Drug Discovery Awards for two programs, supporting its preclinical efforts. Antabio aims to advance its PEi candidate through non-GLP preclinical studies and toward clinical development as a means to enhance existing antibiotic effectiveness for CF patients. The firm positions its work against the global antimicrobial-resistance challenge and seeks to deliver innovative, life-saving therapeutic options. Antabio SAS is a Labège, France–based biopharmaceutical company led by CEO Marc Lemonnier that develops novel antibacterial resistance‑breakers for high‑unmet‑need drug‑resistant infections. Its lead program is a novel inhibitor of bacterial metallo ß‑lactamases (MBLs) intended to be combined with a carbapenem to treat nosocomial drug‑resistant infections. A second program is a first‑in‑class inhibitor of Pseudomonas virulence to be co‑administered with standard‑of‑care antibiotics for long‑term management of chronic respiratory infections. Another program, the Pseudomonas Elastase Inhibitor (PEI), has received CARB‑X funding. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards. The company expects its lead product to enter the clinic in 2019 with anticipated fast track approval. The new Series A funding will be used to accelerate development of the MBL inhibitor program.